New hope capsule tested for Tough-to-Treat thyroid cancer
NCT ID NCT05745363
Summary
This early-stage trial tested a new oral drug called AL2846 for people with an advanced form of thyroid cancer. The cancer had stopped responding to both radioactive iodine and at least one other targeted cancer drug. The main goal was to see if AL2846 could shrink tumors and to check its safety in a small group of 33 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital Of Guilin Medical University
Guilin, Guangxi, 541001, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330029, China
-
Yunnan Cancer Hospital
Kunming, Yunnan, 650011, China
Conditions
Explore the condition pages connected to this study.